Results 291 to 300 of about 167,999 (361)
Gut microbiota in Crohn's disease pathogenesis. [PDF]
Ozbey D, Saribas S, Kocazeybek B.
europepmc +1 more source
ABSTRACT Propolis is a plant‐derived substance collected by honeybees that has a range of potential therapeutic applications. Propolis consists of resins, waxes, and fatty acids, as well as essential oils and other organic compounds. The pharmacologically active components of propolis include phenols and flavonoids, among others.
Yipeng Lin+7 more
wiley +1 more source
Complicated enteroenteric intestinal fistula due to Crohn's disease: a rare case report. [PDF]
Alkhatıb M+4 more
europepmc +1 more source
Interleukin‐1 receptor type II and inflammatory bowel disease: A Mendelian randomization study
This Mendelian Randomization study investigated the association between interleukin‐1 receptor type II (IL‐1RII) and inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC) by utilizing the genome‐wide association studies summary statistics.
Qifan Feng+7 more
wiley +1 more source
Drug Repurposing to Inhibit Oncostatin M in Crohn's Disease. [PDF]
Bahramimehr F+11 more
europepmc +1 more source
There was a positive correlation between apnea/hypopnea index (AHI) index and platelet aggregation and a negative correlation between CD42b and multidrug resistance protein 1 (MRP1). Platelet activation was high while MRP1 expression was low in severe obstructive sleep apnea syndrome (OSAS) independent of smoking, age, and gender.
Cigdem Bayram Gurel+8 more
wiley +1 more source
Nanomedicine for Oral Delivery: Strategies to Overcome the Biological Barriers
Oral delivery is a preferred administration route for many clinical applications, valued for its strong patient compliance. In this review, how nanoparticles are engineered and deployed to overcome the gastrointestinal barriers that impede clinical translation of oral delivery formulations is examined.
Luke J. Kubiatowicz+5 more
wiley +1 more source
Therapeutic mechanisms of exclusive enteral nutrition in Crohn's disease. [PDF]
Tina K+5 more
europepmc +1 more source
Nanozymes emerge as promising therapeutic agents for reactive oxygen species (ROS)‐dependent diseases, offering advantages over traditional biocatalysts through enhanced stability, tunability, and targeting capabilities. This review explores their mechanisms, design strategies, and clinical progress, emphasizing precision medicine potential.
Lihong Zhou+8 more
wiley +1 more source